APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients With Eosinophilic Esophagitis
Latest Information Update: 14 Oct 2025
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Eosinophilic oesophagitis
- Focus Expanded access; Therapeutic Use
- Sponsors Ellodi Pharmaceuticals
Most Recent Events
- 03 Oct 2025 Status changed from recruiting to completed.
- 03 Nov 2021 New trial record